AISR fortnightly report no. 11 – 16 August to 29 August 2021

The fortnightly Australian Influenza Surveillance Report (AISR) includes information about influenza activity, severity, impact, at-risk populations, virology, and vaccine match and effectiveness. It also gives year-to-date data and comparisons.

Downloads

AISR fortnightly report no. 11 – 16 August to 29 August 2021

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
Report
Audience:
Health sector
Language:
English
Description:

The Australian Influenza Surveillance Report (AISR) is compiled from several data sources used to monitor influenza activity and severity in the community. These data sources include:

  • laboratory-confirmed notifications to NNDSS
  • influenza-associated hospitalisations
  • sentinel influenza-like illness (ILI) reporting from general practitioners
  • ILI-related community level surveys
  • sentinel laboratory testing results.

The AISR is published fortnightly during the influenza season, typically between May and October. Influenza activity updates may be published outside of the seasonal period.

Key Messages

It is important to note that due to the COVID-19 epidemic in Australia, data reported from the various influenza surveillance systems may not represent an accurate reflection of influenza activity. Results should be interpreted with caution, especially where comparisons are made to previous influenza seasons. Interpretation of 2020 influenza activity data should take into account, but are not limited to, the impact of social distancing measures, likely changes in health seeking behaviour of the community including access to alternative streams of acute respiratory infection specific health services, and focussed testing for COVID-19 response activities. Current COVID-19 related public health measures and the community’s adherence to public health messages are also likely having an effect on transmission of acute respiratory infections, including influenza.

Activity

  • Influenza-like-illness (ILI) activity in the community remains at historically low levels in 2021. While ILI levels increased between January and May 2021, a gradual decrease has been observed since June.

  • Notifications of laboratory-confirmed influenza have also remained low since April 2020. In the year to date in 2021, there have been 483 notifications to the National Notifiable Diseases Surveillance System (NNDSS) in Australia, of which 21 notifications had a diagnosis date this fortnight.

Severity

  • There is no indication of the potential severity of the 2021 season at this time.

  • In the year to date, of the 483 notifications of laboratory-confirmed influenza, no influenza-associated deaths have been notified to the NNDSS.

  • There have been no hospital admissions due to influenza reported across sentinel hospitals sites since commencement of surveillance in April 2021.

Impact

  • Given the low number of laboratory-confirmed influenza notifications, low community ILI activity, and no hospitalisations due to influenza at sentinel hospital sites, it is likely there is minimal impact on society due to influenza in 2021 to date.

At-risk populations

  • In 2021 to date, adults aged 85 years and older, adults aged 60–69 years, children under 5 years of age, and adults aged 75–84 have the highest influenza notification rates.

Virology

  • To date, 64.4% of notifications of laboratory-confirmed influenza to the NNDSS were influenza A, of which 98.4% were influenza A(unsubtyped) and 1.6% were influenza A(H3N2). Influenza B accounted for 20.3% of notifications, 3.1% were influenza A and B co-infection, 0.2% were influenza C, and 12.0% were untyped.

Vaccine match and effectiveness

  • It is too early to assess vaccine match and effectiveness for this season.

  • Of the 10 samples referred to the WHOCC to date, 1 influenza B/Victoria sample was characterised as antigenically similar to the corresponding vaccine component, while 9 influenza A(H3N2) samples were characterised as antigenically dissimilar.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.